( MENAFN - EIN Presswire) NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal health Incorporated (NYSE:ELAN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting .
Investors have until December 6, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Elanco Animal Health Incorporated securities. The case is pending in the U.
S. District Court of Maryland and is captioned Barpar v. Elanco Animal Health Incorporated, et al.
, No. 24-cv-02912. What is the Lawsuit About? The complaint alleges that Elanco develops products to treat diseases in animals.
Two of the most important treatments in the company's development pipeline are currently being reviewed by the U.S. Food and Drug Administration (“FDA”).
The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad spectrum oral parasiticide covering fleas, ticks and internal parasites. With respect to these treatments, the company stated that the FDA“has all data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June [2024].
” H.
